Improving Quality of Life in Early Parkinson's Disease
Status:
Not yet recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The study will examine 30 patients between ages 50-80, newly diagnosed with early-stage
Parkinson's Disease. Patients will be randomized to receive either Citalopram or
Carbidopa-levodopa. The investigators' primary outcome measure will be change in quality of
life over a prospective period of 6 months. Secondary outcome measures will include change in
mood state and motor symptoms, as well as comparison of improvement between two treatments.
Primary investigators would also like to collect quantitative electroencephalogram (qEEG)
recordings, which is a reading of brain activity as an additional interest of this study.
Primary investigators will assess the qEEG recordings for electrophysiological findings
before and after interventions.
Phase:
N/A
Details
Lead Sponsor:
Western University, Canada
Treatments:
Carbidopa Carbidopa, levodopa drug combination Citalopram Dihydroxyphenylalanine Levodopa